- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01566305
Effects of Buttermilk on Serum LDL Cholesterol Concentrations
The Effects of Buttermilk With or Without Lutein-enriched Egg Yolk on the Serum LDL Cholesterol Concentration of Slightly Hypercholesterolaemic Volunteers
Rationale and objective:
Based on the results of a pilot study, the objective of the present study is to evaluate whether buttermilk lower serum LDL cholesterol concentrations and can prevent the serum LDL cholesterol raising effects of eggs.
Study Design:
The study has a randomized placebo-controlled factorial 2x2 design. The total study duration is 14 weeks, consisting of a 2 weeks run-in period and a 12 weeks experimental period. Subjects will be stratified for age, gender and BMI over the experimental groups.
Study population:
One hundred and eight healthy male and female subjects, aged 18-70 years, with slightly elevated serum total cholesterol concentrations (5.5-8.0 mmol/l).
Intervention:
During the entire study period, volunteers are instructed to consume a diet according to the Dutch dietary guidelines (35 en% fat (10 en% saturated fat), 50-55 en% carbohydrates). During the two weeks run-in period all subjects will drink daily at lunch 100 mL skimmed milk. During the 12 weeks experimental period, a first group of subjects will continue drinking the skimmed milk (control group), while a second group will consume a low-fat buttermilk, a third group skimmed milk enriched with egg-yolk, and a fourth group egg-yolk incorporated into a low-fat buttermilk based beverage. The egg-yolk will be enriched in lutein. Whole egg consumption (others than provided by us) is not allowed during the entire study.
Main study parameters/endpoints:
Measurements will be performed during the run-in period (days 0, 11 and 14) and during the experimental period (days 56, 95 and 98). The main effects (egg-yolk and buttermilk consumption) will be calculated as the absolute differences between values obtained at the end of the experimental (average days 95 and 98) and run-in (average days 11 and 14) periods. The primary endpoint is the change in serum LDL cholesterol concentrations. Secondary endpoints are changes in serum total and HDL cholesterol, triacylglycerol, apoA-I, apoB and hsCRP concentrations.
Study Overview
Status
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6200
- Maastricht University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged between 18 and 70 years
- Fasting serum total cholesterol between 5.5 - 8.0 mmol/l
- Fasting plasma glucose < 7.0 mmol/l
- BMI between 25-30 kg/m2
- non-smoking
- Willingness to abstain for the duration of the study from egg consumption
Exclusion Criteria:
- unstable body weight (weight gain or loss >3 kg in the past 3 months)
- allergic for eggs or egg-rich products
- allergic or intolerant for cow-milk (lactose) based products
- indication for treatment with cholesterol-lowering drugs according to the Dutch Cholesterol Consensus
- use of medication or a diet known to affect serum lipid or glucose metabolism - active cardiovascular disease (for instance congestive heart failure) or recent (<6 months) event, such as acute myocardial infarction or cerebro-vascular accident
- not willing to stop the consumption of vitamin supplements, fish oil capsules or products rich in plant stanol or sterol esters 3 weeks before the start of the study
- men: consumption of >21 alcohol consumptions a week
- women: consumption of >14 alcohol consumptions a week
- abuse of drugs
- pregnant or breastfeeding women
- participation in another biomedical study within 1 month prior to the screening visit
- having donated blood (as blood donor) within 1 month prior to the screening visit or planning to do so during the study
- impossible or difficult venipuncture as evidenced during the screening visits
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Buttermilk with added egg yolk
|
Buttermilk with added egg yolk
|
Experimental: Buttermilk without added egg-yolk
|
Buttermilk without added egg-yolk
|
Experimental: Skimmed milk with added egg-yolk
|
Skimmed milk with added egg-yolk
|
Placebo Comparator: Skimmed milk without added egg yolk
|
Skimmed milk without added egg yolk
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in serum LDL cholesterol concentrations
Time Frame: LDL cholesterol will be measured at day 0, 11, 14, 56, 95 and 98 during the study
|
LDL cholesterol will be measured at day 0, 11, 14, 56, 95 and 98 during the study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in serum total and HDL cholesterol, triacylglycerol, apoA-I, apoB and hsCRP concentrations
Time Frame: Serum total and HDL cholesterol, triacylglycerol, apoA-I and ApoB will be measured at day 0, 11, 14, 56, 95 and 98 during the study. hsCRP concentrations will be measured at day 11, 14, 95 and 98.
|
Serum total and HDL cholesterol, triacylglycerol, apoA-I and ApoB will be measured at day 0, 11, 14, 56, 95 and 98 during the study. hsCRP concentrations will be measured at day 11, 14, 95 and 98.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jogchum Plat, Dr., Maastricht University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL33461.068.10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
Nanjing Medical UniversityNot yet recruitingCardiovascular Disease
-
National Human Genome Research Institute (NHGRI)Active, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
AmgenCompletedCardiovascular DiseaseUnited States, Australia
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
Clinical Trials on Buttermilk with added egg yolk
-
Eunice Kennedy Shriver National Institute of Child...CompletedSmith-Lemli-Opitz SyndromeUnited States
-
University of California, DavisCompletedObesity | OverweightUnited States
-
Tampere University HospitalOulu University Hospital; University of OuluRecruiting
-
Mahidol UniversityCompletedMalnutrition, ChildThailand
-
Wageningen UniversityCompleted
-
Peter SiesjöSkane University Hospital; Lantmannen Medical ABRecruiting
-
Azienda Ospedaliera Specializzata in Gastroenterologia...CompletedHealthy Subjects | Glycemic Response | Insulinemic ResponseItaly
-
Peter SiesjöLund UniversityRecruiting
-
Edith Cowan UniversityFlinders University; The University of Western AustraliaCompleted
-
University of Alabama, TuscaloosaMcCormick Science InstituteRecruitingCardiometabolic SyndromeUnited States